NSA Labs Cuts Drug Development Timelines with Proscia’s Digital Pathology Platform
Event summary
- NSA Labs has used Proscia’s Concentriq® platform since 2018 to accelerate neurohistology study results for biopharmaceutical clients.
- The CRO has streamlined 750 studies by centralizing images, data, and workflows on the platform.
- Concentriq enables direct sponsor access to histology images and study results, reducing decision-making time.
- 16 of the top 20 pharmaceutical companies rely on Concentriq for pathology from discovery to diagnostics.
The big picture
NSA Labs’ success with Proscia’s platform underscores the growing reliance on digital tools to accelerate drug development. As pharmaceutical companies seek faster, more collaborative pathways from discovery to diagnostics, Concentriq’s role in centralizing pathology data could set a new industry standard for efficiency and decision-making.
What we're watching
- Platform Scalability
- Whether Proscia can sustain Concentriq’s adoption pace among top pharmaceutical firms.
- Competitive Differentiation
- How NSA Labs’ proprietary technologies will influence its position in high-throughput neurohistology.
- Industry Standardization
- The pace at which digital pathology platforms become essential for biopharmaceutical R&D workflows.
Our editorial coverage: